About Cogent Biosciences, Inc. - Common Stock (COGT)
Cogent Biosciences Inc. is a biotechnology company focused on developing innovative therapies for genetically defined diseases. The company leverages its expertise in targeted drug development to create treatments that address the underlying genetic causes of various conditions, with a particular emphasis on rare diseases and severe forms of cancer. By utilizing advanced technologies and scientific research, Cogent aims to bring more effective therapeutic options to patients who are often underserved by existing treatments, advancing the field of precision medicine. Read More
Cogent Biosciences (NASDAQ: COGT) experienced a dramatic surge in its stock price, hitting a 52-week high in early July 2025, following the announcement of highly positive "breakthrough results" from its SUMMIT clinical trial for bezuclastinib. This investigational drug, aimed at non-advanced systemic mastocytosis (NonAdvSM), demonstrated significant efficacy and a favorable
Bezuclastinib met all primary and secondary endpoints in a Phase 3 trial for non-advanced systemic mastocytosis, with analysts highlighting strong efficacy, safety, and commercial potential.
Shares of Sony Group Corporation (NYSE: SONY) fell during Wednesday’s session after the company reported third-quarter financial results and revised guidance above estimates and shared plans to list its financial arm in October 2025.
